Stock vs Stock Comparison

Apellis Pharmaceuticals, Inc. vs AbCellera Biologics Inc.

APLS wins the Tale of the Tape 6–2.

APLS
ABCL

🏆 Tale of the Tape

62
APLSABCL
2.2%Profitability (Net Margin)-194.9%
224.4xValuation (P/E)
7.2%Efficiency (ROIC)-12.4%
7/9Health (Piotroski F)4/9
2.4Safety (Altman Z)
28.5%Growth (Rev YoY)160.6%
1.90xBalance Sheet (D/E)0.40x
0.89%FCF Yield

Green = winner in each category. Higher is better except P/E (lower = cheaper).

Fundamentals

MetricAPLSABCL
Market Cap$5.2B
P/E Ratio224.4x
Forward P/E-131.1x
P/B13.82x
Dividend Yield
Beta0.29

Quantitative Metrics

MetricAPLSABCL
DCF Fair Value$9.27
DCF Upside
Piotroski F7/94/9
Altman Z2.39
Beneish M-2.45
FCF Yield0.89%
Net Debt/EBITDA-1.5x
ROIC7.2%-12.4%
WACC7.7%
ROIC – WACC-0.5pp
Gross Margin89.8%
Net Margin2.2%-194.9%
Rev Growth YoY28.5%160.6%
Sharpe (1Y)
Max Drawdown 3Y
FCF Payout Ratio

APLS Price

Loading chart...

ABCL Price

Loading chart...

ETF Exposure

APLS found in:

VBK0.13%
VHT0.05%
VONG0.01%

ABCL found in:

GWX0.09%
SPDW0.01%

More Comparisons

Quant metrics computed from financial statements and 1,200+ trading days. Correlation is Pearson coefficient on daily log returns. Not investment advice.

APLS vs ABCL: Head-to-Head Analysis

Apellis Pharmaceuticals, Inc. (APLS) and AbCellera Biologics Inc. (ABCL) represent two companies in the Healthcare sector. In our quantitative Tale of the Tape scoring, APLS leads 6–2 across nine fundamental and risk metrics including profitability, valuation, capital efficiency, and financial health.

In terms of capital efficiency, APLS generates a return on invested capital (ROIC) of 7.2% compared to ABCL's -12.4%. This suggests APLS is more effective at deploying capital to generate shareholder returns.

APLS appears in 3 ETFs tracked by SecuritiesDB, while ABCL appears in 2 ETFs. Investors holding broad-market ETFs may already have indirect exposure to both stocks.

Frequently Asked Questions

Which stock is the better investment, APLS or ABCL?

Our quantitative analysis compares APLS and ABCL across nine fundamental dimensions. APLS wins the Tale of the Tape 6–2. However, stock selection depends on your individual risk tolerance, time horizon, and portfolio context. These metrics are computed from SEC filings and market data — they are not investment recommendations.

Are APLS and ABCL correlated?

Correlation data is not yet available for this pair. Check back after both stocks have sufficient trading history.

How is the Tale of the Tape scored?

The Tale of the Tape compares both stocks across nine categories: profitability (net margin), valuation (P/E), efficiency (ROIC), health (Piotroski F-Score), safety (Altman Z-Score), growth (revenue YoY), risk (Sharpe ratio), leverage (debt-to-equity), and cash generation (FCF yield). The stock that wins more categories takes the overall score. Lower P/E and lower debt-to-equity count as wins.